Please ensure Javascript is enabled for purposes of website accessibility

Concerns Swirl Over Critical Drug Launch

By Dave Williamson - Apr 4, 2013 at 7:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can this pharmaceutical company shake lingering safety profile fears?

In the following video, Motley Fool health-care analyst David Williamson discusses Ariad Pharmaceuticals (NASDAQ: ARIA), as the company's stock reverses direction today, up 3% following yesterday's tumble. He notes the results of a boutique institutional research survey that found Ariad's new drug Iclusig to have toxicity concerns, and even more negative information coming from the FDA, citing blood clots and liver toxicity. David tells investors what the potential for this drug is, and whether it has a shot at success on the market despite these safety concerns.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$93.75 (-0.94%) $0.89
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$77.24 (0.14%) $0.11
Novartis AG Stock Quote
Novartis AG
$91.25 (-0.74%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.